Lymphoblastic Leukemia Clinical Trial
Official title:
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia
The purpose of this study is to deliver dual-targeting CAR-T cell therapy (CART 2219.1) as a salvage treatment to patients with relapsed/refractory B-lineage leukaemia in place of stem cell transplant or irradiation.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05043571 -
CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia
|
Phase 1 | |
| Completed |
NCT00988013 -
Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies
|
N/A | |
| Completed |
NCT00866749 -
Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
|
Phase 2 | |
| Completed |
NCT01615809 -
Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia
|
Phase 2 | |
| Recruiting |
NCT05993949 -
Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia
|
Phase 1 | |
| Recruiting |
NCT05848687 -
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05885464 -
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
|
Phase 1/Phase 2 | |
| Terminated |
NCT01100658 -
Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors
|
N/A | |
| Recruiting |
NCT05194397 -
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
|
Phase 2 | |
| Completed |
NCT00388531 -
Depocyte in the Treatment of CNS Relapse in Patients With Lymphoblastic Leucemia or Very Aggressive Lymphoma
|
Phase 2 | |
| Completed |
NCT00354120 -
Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04747912 -
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
|
Phase 2 | |
| Recruiting |
NCT05648019 -
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
|
Phase 2 | |
| Completed |
NCT03328104 -
Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma
|
Phase 1 | |
| Terminated |
NCT00776373 -
Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05664230 -
Efficacy of Osteopathic Treatment on the Side Effects of Curative Treatments of Lymphoblastic Leukemia in Pediatrics
|
||
| Recruiting |
NCT03564704 -
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL
|
Phase 2/Phase 3 | |
| Completed |
NCT04145531 -
An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT06175702 -
Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL
|
||
| Terminated |
NCT00967343 -
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
|
Phase 2/Phase 3 |